Starton Therapeutics
Hemal Shah is an Executive bringing over 20 years of experience in health economics and outcomes research (HEOR), real-world evidence generation, pricing, market access, value demonstration, and health policy.
Former Senior Vice President, Medical Affairs, Healthcare Quality, Policy and Outcomes at Optimer Pharmaceuticals and Executive Director of HEOR at Boehringer Ingelheim. She holds a Doctor of Pharmacy from The State University of New Jersey, a BSc. in Pharmacy, and a BSc. in Molecular & Cell Biology from the University of Connecticut and completed a post-doctoral fellowship in outcomes research at Geisinger Health System/Novartis.
This person is not in any offices
Starton Therapeutics
Starton Therapeutics is a clinical-stage biotechnology company that is transforming standard-of-care therapies with proprietary transdermal technology, so people with cancer can receive continuous treatment to live better, longer.